1. Beerepoot L, Witteveen P, Groenewegen G, Fogler W, Sim B, Sidor C, Phillips E, Zonnenberg B, Schramel F, Gebbink M, Voest E (2001) Preliminary results of a phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc AACR-NCI-EORTC (abstract 34)
2. Bhargava P, Marshall J, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong V, Kato A, Hawkins M (1999) A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5: 1989–1995
3. Blumenschein G, Fossella F, Pisters K, Khuri F, Lu C, Kies M, Glisson B, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong W, Herbst R (2002) A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol 21: 314a (abstract 1254)
4. Brahmer J, Kelsey S, Scigalla P, Hill G, Bello C, Elza-Brown K, Donehower R (2002) A phase I study of SU6668 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 21: 84a (abstract 335)
5. Britten C, Rosen L, Kabbinavar F, Rosen P, Mulay M, Hernandez L, Brown J, Bello C, Kelsey S, Scigalla P (2002) Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proc Am Soc Clin Oncol 21: 28b (abstract 1922)